Conflicts of Interest
|
|
- Thomasina Foster
- 8 years ago
- Views:
Transcription
1 Anticoagulation 2014 Bruce Ritchie MD, FRCPC 3 Director VTE Clinic, UofA Hospital Director Comprehensive Bleeding Disorder Clinic Director Comprehensive Rare Blood Disorder Clinic Director Canadian BioSample Repository (CBSR) Mar-2014
2 Conflicts of Interest Principle Investigator in Pharmaceutical Trials including: Fragmin, Lovenox, XiMelagatran, Rivaroxaban, Dabigatran, Apixaban, Edoxaban Unpaid consulting advice to: Baxter, Bayer, Boehringer- Ingelheim, Canadian Blood Service, Canadian Hemophilia Society, Covidien, CSL Behring, Dyax, Leo Pharmaceuticals, Novartis, Novo Nordisk, Pharming, Pfizer, Sanofi, Talecris, Wyeth In lieu of Honoraria, I request that donations be made to the University of Alberta to fund summer students ($1300/month X 4 = $5200) I have received funding for Investigator Initiated studies (biobanking) from: Baxter, CSL Behring, Novartis, Novo Nordisk, Pfizer, Wyeth. Pending: Bayer, Boehringer-Ingelheim, Leo, Sanofi.
3
4 Venous ThromboEmbolism: New Anticoagulant Drugs How do they work 2.How do we measure them 3.How do we reverse them 4.How do we manage elective Surgery Bruce Ritchie MD, FRCPC 3 Director VTE Clinic, UofA Hospital Director Comprehensive Bleeding Disorder Clinic Director Comprehensive Rare Blood Disorder Clinic Director Canadian BioSample Repository (CBSR)
5 Adapted from Wikipedia 9
6 Microparticles & Tissue Factor, green=tf, red=platelets, fibrin=blue, platelets/tf=yellow, platelets/fibrin=turquoise, platelets/tf/fibrin=white
7 Thromboembolic Disease in Alberta Incidence 108 in 100, ,584,304 people in Alberta in 2011; 4 million (Mar, 2013) 3,871 new cases per year in Alberta; 4,320 (Mar 2013) Recurrence in 30% - 40% 2, recurrent cases per year in Alberta (Mar-2013) Severe Post thrombotic Syndrome 2,3,4 Severe PTS in 3% at 2 years 2 ( ), 6% at 10 years 3 ; ( ) Disability costs $5,500-7, % of symptomatic PE s are fatal within 1 hour 4,5, 40% at 30 days 6 1. Roger VL, et al. Heart disease and stroke statistics update: A report from the american heart association. Circulation. 2012;125:e2-e220 ; 2. Schulman S, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4: ; 3. Kahn SR, et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Annals of Internal Medicine. 149(10): , 2008 Nov 18.
8 VTE Clinical Features Anderson FA Jr, et al. Incidence of VTE increases with age: Arch Intern Med. 1991;151: Fihn SD; Callahan CM; Martin DC; McDonell MB; Henikoff JG; White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Annals of Internal Medicine. 124(11):970-9, 1996 Heit JA, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med. 2000;160: Schulman S, et al. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:
9 Risk of VTE Recurrence Florent Boutitie, Laurent Pinede, Sam Schulman, Giancarlo Agnelli, Gary Raskob, Jim Julian, Jack Hirsh, Clive Kearon. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants data from seven trials. BMJ 2011;342:d3036. doi: /bmj.d3036
10 Long-term Prophylaxis Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med Feb 6;336(6): Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med Mar 25;340(12): Erratum in: N Engl J Med 1999 Jul 22;341(4):298.
11 Pulmonary Embolism: A Life-threatening Disease Cumulative mortality following acute PE Mortality rate (%; excluding PE first recognised at necropsy) % Mortality At 3 months International Cooperative Pulmonary Embolism Registry N= Time from diagnosis (days) PE=pulmonary embolism Goldhaber SZ et al; for ICOPER. Lancet. 1999;353:
12 Kahn SR, et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Annals of Internal Medicine. 149(10): , 2008 Nov 18. Schulman S, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4: Post Thrombotic Syndrome in Canada
13 Warfarin & Intracranial Hemorrhage in Finland 1993 to 2008
14 Warfarin & Intracranial Hemorrhage in Finland 1993 to , introduction of PCC
15 Reversal of Coumadin - PCC Nitzki-George D. Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Ann Pharmacother 2013;47:
16 Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal. Dowlatshahi D et al; on behalf of the Canadian PCC Registry (CanPro) Investigators* Stroke. 2012;43:
17 Drug New Oral Anticoagulants Indication targ et Peak T ½ Clearance Drug Interactions Antidote Dabigatran Rivaroxaban Apixaban A Fib DVT/PE Hip/Knee A Fib DVT/PE Hip/Knee A Fib Hip/Knee II 1-4 h h 85% renal Rifampin, quinidine, amiodarone, Potent P-gp inhibitor Xa h 7-11 h 66% renal really 33% Potent CYP3A4, P-gp inhibitor Xa 3-4 h 12 h 27% renal Potent CYP3A4 inhibitor Edoxaban No Xa 1-2 h 6-11 h 35% renal Potent CYP3A4, P-gp inhibitor apcc PCC PCC PCC Betrixaban No Xa 3-4 h 20 h <8% renal Fonda Hip/Knee Abd Surg Xa 2 h 17 h 100% renal protamine
18 Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial 1. Hart RG, Diener HC, Yang S, etal. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RELY trial. Stroke 2012;43: doi: /STROKEAHA Eikelboom JW, et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial Circulation. 2011;123: , published online before print May , doi: /circulationaha
19 Eikelboom JW, et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial Circulation. 2011;123: , published online before print May , doi: /circulationaha
20 Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. NEJM Online 13-Mar DOI: /NEJMp
21 Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism The EINSTEIN PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012;366:
22 Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism The EINSTEIN PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012;366:
23 Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism The EINSTEIN PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012;366:
24 Apixaban in Patients with Atrial Fibrillation Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser S, Rafael Diaz, M.D., Talajic M, Zhu J, Pais P, M.B, Budaj A, Parkhomenko A, Jansky A, Commerford P, Tan RS, Sim K-H, Lewis BS, Van Mieghem W, Lip GJY, Kim JH, Lanas- Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O Donnell M, Lawrence J, Lewis G, Afzal, R, and Yusuf S, for the AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011;364:
25 Thrombin Time Ratio Best Approximates Dabigatran Plasma Levels van Ryn J; Stangier J; Haertter S; Liesenfeld K-H; Wienen W; Feuring M; Clemens A. Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of 43 anticoagulant activity. Thrombosis and haemostasis [ ] yr:2010 vol:103 iss:6 pg:
26 Standardized Hemoclot Thrombin Time van Ryn J; Stangier J; Haertter S; Liesenfeld K-H; Wienen W; Feuring M; Clemens A. Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of 44 anticoagulant activity. Thrombosis and haemostasis [ ] yr:2010 vol:103 iss:6 pg:
27 Effect of Rivaroxaban On Coagulation Parameters: aptt Ratio 45 Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundamental & Clinical Pharmacology 26 (2012) 27 32
28 Effect of Apixaban on anti Xa assays Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis (2011) 32:
29 Reversal of Rivaroxaban and Dabigatran Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate : A Randomized, Placebo- Controlled, Crossover Study in Healthy Subjects Elise S. Eerenberg, Pieter W. Kamphuisen, Meertien K. Sijpkens, Joost C. Meijers, Harry R. Buller and Marcel Levi. Circulation October 4, 2011
30 3ZoNBF2cTx7FZlR4qrBObwvFcmhQ%3D%3D
31 Reversal of Rivaroxaban and Dabigatran Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate : A Randomized, Placebo- Controlled, Crossover Study in Healthy Subjects Elise S. Eerenberg, Pieter W. Kamphuisen, Meertien K. Sijpkens, Joost C. Meijers, Harry R. Buller and Marcel Levi. Circulation October 4, 2011
32 Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban Dabigatran Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban A randomised crossover ex vivo study in healthy volunteers. Raphael Marlu; Enkelejda Hodaj; Adeline Paris; Pierre Albaladejo; Jean Luc Crackowski; Gilles Pernod. Thromb Haemost 2012; 108:
33 FEIBA monograph: df Reversing NOACs: FEIBA (Activated PCC) Contains Factors II, IX, and X, mainly non-activated, and Factor VII mainly in the activated form. Dose: IU/kg
34 Alternative: PCC and rfviia + Octaplex/Beriplex 40 IU/kg NovoSeven (rfviia) 1 mg 1. Octaplex monograph: roved.pdf&t= &hash=0ab78e2e273f669f418af3633c86b3bf07ab3da4 2. Beriplex monograph: 3. NovoSeven monograph:
35 Strategies for treating bleeding on NOACs Minor or Moderate bleeding: hold NOAC; measure creatinine, PTT/PT; local measures Severe/Life-threatening bleeding: hold NOAC; measure creatinine, PTT/PT; local measures, PLUS Dabigatran Activated charcoal suspension if less then 2 hrs Consider dialysis Reverse with FEIBA U/kg or PCC+rFVIIa Rivaroxaban Reverse with PCC U/kg Nitzki-George D, Wozniak I, Caprini J. Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Ann Pharmacother 2013;47: van Ryn J, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:
36 Availability of PCCs (Octaplex. Beriplex) in Alberta North Zone: 37 hospitals, not LaCrete (RHIg), Vilna Edmonton Zone: 12 hospitals, not CCI (IVIg), East Edmonton Health, Gibbons Central Zone: 29 hospitals (all) Calgary: 13 hospitals (all) South: 12 hospitals, not Coaldale, Oyen (rbcs & RhIg) Total: 103 hospitals in Alberta almost all the hospitals that carry blood products. Alberta Health Services
37 Availability of apccs (FEIBA) in Alberta PCC availability, includes most stroke sites (?Canmore, Medicine Hat), & FVIII Inhibitor patients Peace River Community Health Centre Queen Elizabeth II Hospital (Grande Prairie) Sturgeon Hospital (St. Albert) University of Alberta Hospital Royal Alexandra Hospital Misericordia Hospital Grey Nuns Hospital Hinton Healthcare Centre Westlock Healthcare Centre Red Deer Hospital Foothills Hospital Alberta Children s Hospital Chinook Regional Hospital (Lethbridge) Alberta Health Services
38 FEIBA (apcc) Monograph
39 apccs and thrombosis Post-marketing surveillance: 1. the risk of thrombosis ranged from 0/4500 infusions 4, 3.18/100,000 infusion in 18 years 5, 8.24/100,000 infusions 3, and 4.05/100,000 infusions 2. Risk factors were overdose/frequent dosing in 30-80% 2. Combining apcc with tranexamic acid showed no excess thrombosis HOLMSTROM M, TRAN HTT, HOLME PA.Combined treatment with APCC (FEIBAÒ) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A a two-centre experience. Haemophilia (2012), 18, DOI: /j x 2. EHRLICH HJ, HENZL MJ, GOMPERTS ED. Safety of factor VIII inhibitor bypass activity(feibaò): 10-year compilation of thrombotic adverse events. Haemophilia (2002), 8, ALEDORT LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Journal of Thrombosis and Haemostasis, 2: DIMICHELE D, & NEGRIER C. A retrospective post licensure survey of FEIBA efficacy and safety. Haemophilia (2006), 12, DOI: /j x 5. Evaluating the Thrombotic Safety Profile of Factor VIII Bypassing Activity (FEIBA). Adams J, Lee D, Yoon BS. Poster, WFH World Congress 02-Jun-2008
40 Rivaroxaban and enoxaparin have similar effects on Anti-Factor Xa activity beyond 24 hours Enoxaparin has a half-life of 4-7 hours and can be dosed either OD or BID Adapted from Kubitza et al., ISTH 2005; Lovenox Product Monograph, 2010
41 Questions 59
42 Questions FOTOS DE LAURENT SCHWEBEL: 60
43 ClinicalTrials.gov The future for DOAC reversal - Idarucizumab
44 The future for DOAC reversal - Andexanet Alfa Neal Shah. Reversal Agents for Anticoagulants: Focus on Andexanet Alfa. AMSRJ Spring 2014; 1, No. 1
45 Xarelto PM, July 18, 2012; Eliquis PM November 27, 2012; Pradaxa PM November 12, 2012 Rivaroxaban Determine patients risk of bleeding Discontinuation Before Elective Invasive or Surgical Procedures Time to discontinue medication prior to procedure Dabigatran Determine patients risk of bleeding Apixaban Determine patients risk of bleeding Standard risk High risk of bleeding or major surgery Standard risk High risk of bleeding or major surgery Standard risk High risk of bleeding or major surgery At least 1 day 2-4 days ml/min Estimate CrCl ml/min 80 ml/min ml/min Estimate CrCl ml/min 80 ml/min At least 1 day At least 2 days days days 1-2 days 1 day 4 days 2-3 days 2 days Recommended May be considered
46 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published online before print August Circulation DOI: /CIRCULATIONAHA Xarelto PM, July 18, 2012; Eliquis PM November 27, 2012; Pradaxa PM November 12, 2012
47 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published online before print August Circulation DOI: /CIRCULATIONAHA Xarelto PM, July 18, 2012; Eliquis PM November 27, 2012; Pradaxa PM November 12, 2012
48 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published online before print August Circulation DOI: /CIRCULATIONAHA Xarelto PM, July 18, 2012; Eliquis PM November 27, 2012; Pradaxa PM November 12, 2012
49 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published online before print August Circulation DOI: /CIRCULATIONAHA Xarelto PM, July 18, 2012; Eliquis PM November 27, 2012; Pradaxa PM November 12, 2012
50 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published Xarelto online before PM, July print 18, 2012; August Eliquis PM Circulation November 27, DOI: 2012; /CIRCULATIONAHA Pradaxa PM November 12, 2012
51 ASA for VTE prophylaxis after unprovoked VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne C. Kirby, Rebecca Mister, Paolo Prandoni, Timothy A. Brighton, for the INSPIRE Study Investigators*. Published Xarelto online before PM, July print 18, 2012; August Eliquis PM Circulation November 27, DOI: 2012; /CIRCULATIONAHA Pradaxa PM November 12, 2012
52 Rivaroxaban Clinical Programme Overview: > 60,000 Patients Enrolled VTE prevention after major orthopaedic surgery VTE prevention in hospitalized medically ill patients VTE treatment Stroke prevention in atrial fibrillation Secondary prevention of acute coronary syndromes Phase III RECORD1 RECORD2 RECORD3 RECORD4 EINSTEIN-DVT EINSTEIN-PE EINSTEIN-EXT Customized Dose 10 mg od (2 weeks, knee; 5 weeks, hip) 10 mg od (5 weeks) 15 mg bid for first 3 weeks 20 mg od 3, 6, or 12 months 20 mg od 15 mg od for CrCl ml/min 2.5 mg bid 5 mg bid
53 omy_page1.html
54 Bleeding with NOACs
55 Bleeding with NOACs
56 Bleeding with NOACs
57 Bleeding with NOACs
58 Long-term Prophylaxis Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med Mar 25;340(12): Erratum in: N Engl J Med 1999 Jul 22;341(4):298.
59 Last updated: February 2014 Einstein Choice- Study Design Randomized, double-blind, event-driven, superiority study Objective of the study: Demonstrate that both rivaroxaban 20 mg or 10 mg are superior in the long term secondary prevention of recurrent VTE to ASA 100 mg with comparable rates of major bleeding Patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment* Day 1 N~ 2,850 R Rivaroxaban 20 mg od n~ 950 Rivaroxaban 10 mg od n~ 950 ASA 100mg od n~ month treatment duration 1 month observation period Primary endpoint: Fatal or non-fatal symptomatic recurrent VTE Study Start Date: February 2014 Estimated Study Completion Date: December * Completed 6 to 12 months (± 1 month) with interruption of anticoagulation 1 week at randomisation
60 Last updated: February 2014 Non-interventional study: Xarelto (XALIA) study design Prospective, non-interventional cohort field study Objective: To collect real-life data on adverse events (AEs), bleeding, thromboembolic events and mortality in patients diagnosed with actue DVT treated with rivaroxaban or standard of care (SOC) Study population: Patients (N~4800) with diagnosis of acute DVT (not PE) and with an indication for anticoagulant therapy for 3 months Type, dose and duration of drug used at discretion of attending physician *Protocol does not define exact referral dates for follow-up visits Rivaroxaban for 3 months N~2400 Investigators to collect data at initial visit, at 1 month and then quarterly* SOC: e.g. initial treatment with LMWH or fondaparinux, followed by VKA for 3 months N~2400 Study Start Date: June 2012 Estimated Study Completion Date: March 2015 (1 month after end of treatment) Final assessment Primary outcomes: Major bleeding events, symptomatic recurrent venous thromboembolic events, all-cause mortality DVT, deep vein thrombosis; LMWH, low molecular weight heparin; PE, pulmonary embolism; SOC, standard of care; VKA, vitamin K antagonist
61 Figure 1. Adjusted relative risks for bleeding complications and 95% Cls according to age category. Relative risks were obtained by Cox regression using combined retrospective and prospective cohorts with adjustment for intensity of warfarin therapy and deviation in prothrombin time ratio. Fihn SD; Callahan CM; Martin DC; McDonell MB; Henikoff JG; White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Annals of Internal Medicine. 124(11):970-9, 1996 Jun American College of Physicians. 7
62 Factor VII, Tissue Factor & Factor X g002.htm Pedersen LG. Lee Pedersen s work in theoretical and computational chemistry and biochemistry. World J Biol Chem February 26; 2(2): doi: /wjbc.v2.i
63 Factor X activation of Thrombin 81 Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, and Prcahl JT: Williams Hematology, 8 th Ed:
64 Low Molecular Weight Heparins Rapid onset of action - Peak 4-6 hr Half life 3-4 h 100% renal excretion & 100% bioavailability Predictable and consistent anticoagulant effects No requirement for routine coagulation monitoring can do anti-xa Reversible w protamine 1mg/100u, but only 60% reversible and protamine is a potent anticoagulant when you overdose. Avearge size (60%) less then 8,000 daltons (vs UFH 3-4 kdaltons) 82
65 Low Molecular Weight Heparins Drug Mol Wt target Peak T ½ Clearance Antidote UF Heparin 15 kda II, Xa 1-4 hr 3-4 hr Endothelial / renal Protamine Dalteparin 4.5 kda Xa 4-6 hr 3-4 hr renal Protamine 60% Enoxaparin 4.5 kda Xa 4-6 hr 3-4 hr renal Protamine 60% Tinzaparin 4.5 kda Xa 4-6 hr 3-4 hr renal Protamine 60% Fondaparinux 1.7 kda Xa 2 hr hr renal apcc, Txa
66 Enoxaparin significantly reduces major ischaemic events when compared with UFH in the treatment of thromboembolic diseases 1. Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, Langer A, Califf R, Fox K, Premmereur J, Bigonzi F, Stephens J, Weatherley B. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: Antman EM, McCabe C, Gurfinkel E, Turpie A, Alexander G, Bernink P, Salein D, de Luna A, Fox K, LaBlanche J-M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, Elias D, Grigg A, Musset D, Rodgers G, Trowbridge A, Yusen R, Zawilska K. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight-heparin compared with intravenous heparin for treatment of pulmonary embolism. Ann Intern Med 2004;140:
67 Thromboembolic complications of a subtherapeutic INR 501 patients with INR INR units below lower limit of target INR included (280 with MHV, 221 with AF and CHADS2 score 3). LMWH was prescribed for 64 patients (12.8%). Seven patients had a TE (1.40%; 95% confidence interval 0.68, 2.86%; 5.58 events for 100 patients year). All occurred within 14 days. If only patients not bridged, incidence of TE was 1.14% (5 of 437 patients; 95% confidence interval 0.49, 2.64%; 4.58 events for 100 patients year). There were no major bleeding events. Dentali F, et al. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. Am. J. Hematol. 87: , 2012
68 Prothrombin Complex Concentrates vs apcc Octaplex, OctaPharma 500 U/20 ml Beriplex, CSL Behring 500 U/20mL FEIBA, Baxter U/20 ml U/50ml Units reqd to correct ptt FFP 1U/mL, ml II U/mL VII U/mL IX U/mL X U/mL C U/mL S U/mL Z other Yes Heparin added, low amnt FVIIa Yes Heparin, ATII added 28-38, Trace IIa 20-40, 89-98% FVIIa= 50U= 37 mcg 17-44, Trace IXa 24-28, Trace Xa Activated Protein C (APC) Activated Protein C, FVIII 0.1U/U CPD, ABO compatible 1. Diane Nitzki-George, Izabela Wozniak, Joseph A Caprini. Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Ann Pharmacother 2013;47: FEIBA NF monograph 3. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004;10(suppl 2):10-6
69 Once-Daily Dosing Associated With Higher Adherence 10,697 adult AF patients with full insurance drug coverage, newly initiated on diabetes or antihypertensive medication Those (n=8,256) on once daily regimens had a 26% higher adherence than those (n=2,441) on twice daily regimens Among those aged 65 years, once daily medication was associated with Compliant Patients (%) (medication possession ratio, MPR) a 52% higher probability of being compliant P<0.001 OD Total Population 65 years old 1. Laliberté F et al. Adv Ther 2012; 29: Laliberté F et al. Patient (2013) 6: DOI /s BID P=0.017 Compliant Patients (%) (proportion of days covered, PDC) P<0.001 OD P<0.001 BID P<0.001 P< Months since initiation of therapy
70 aptt variable among sites/reagents van Ryn J; Stangier J; Haertter S; Liesenfeld K-H; Wienen W; Feuring M; Clemens A. Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of 88 anticoagulant activity. Thrombosis and haemostasis [ ] yr:2010 vol:103 iss:6 pg:
71 aptt variable among sites/reagents Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study. Dager WE, Gosselin RC, Kitchen S, and Dwyre D. 89 Ann Pharmacother 2012;46:
72 Diluted Thrombin Time to Measure Dabigatran Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy. Am J Clin Pathol 2012;137: DOI: /AJCPAU7OQM0SRPZQ 90
73 Activated Charcoal for removal of Dabigatran Dabigatran etixilate is lipophilic, & binds to Activated Charcoal Dabigatran etexilate in water (ph ) + Activated charcoal, Dabigatran etexilate could not be detected, > 99.99% adsorbed Dabigatran in human plasma pool at 470 and 940 ng/ml + Active charcoal (125 mg/ ml) or a 1:11 dilution. Dabigatran levels to <1.01 ng/ml. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: doi: /TH
74 Hemodialysis for removal of Dabigatran 1. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rfviia) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: doi: /blood Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46:e21. doi: /aph.1R Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61: doi: /j.ajkd
Comparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationReversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI
Reversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI Novel anticoagulants? Dabigatran (Pradaxa) Stroke and systemic
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationTo assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNovel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
More informationNo more rat poison? New oral anticoagulants and perioperative considerations
1 No more rat poison? New oral anticoagulants and perioperative considerations Jerrold H. Levy, MD, FAHA, FCCM Professor Department of Anesthesiology/Critical Care Duke University School of Medicine Durham,
More informationTo provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationRecommendation for the Reversal of Novel Anticoagulants in Emergent Situations
Lauren Edwards PharmD Candidate 2016 Truman Medical Center, Lakewood Preceptor: Dr. Melissa Gabriel June 11, 2015 Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations Background
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationHome treatment of VTE
Home treatment of VTE Prof. Adel El-Etriby Ain-Shams University Venous Thromboembolism (VTE): The DVT and PE Continuum Migration Embolus Thrombus VTE refers to a continuum of disease that begins with DVT
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationCoagulation issues and bridging. Joost van Veen Consultant Haematologist - STHFT
Coagulation issues and bridging Joost van Veen Consultant Haematologist - STHFT new oral anticoagulants NOAC New oral anticoagulants NOAC Novel oral anticoagulants NOAC Non vitamin K oral anticoagulants
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationMANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationThe importance of adherence and persistence: The advantages of once-daily dosing
The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr
More informationAnticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs)
Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs) Prof. P. HAINAUT Médecine Interne - Maladie Thromboembolique Cliniques Univ. Saint Luc - UCL Background Direct Oral
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationDirect Oral Anticoagulants (DOACs) Who Gets What?
Direct Oral Anticoagulants (DOACs) Who Gets What? Kathryn Hassell, MD Professor of Medicine, Division of Hematology University of Colorado Denver Disclosures No financial or commercial conflicts of interest
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationXarelto and the New Orals
Xarelto and the New Orals in the ER Peter L. Gross MD M.D., MSc M.Sc., FRCP(c) Associate Professor Thrombosis and Atherosclerosis Research Institute McMaster University Thrombosis Clinic Director, Juravinski
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More informationAdherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationRivaroxaban. Practical Experience in the Cardiology Setting. Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationDec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More information